Addex Therapeutics

company

About

Addex Therapeutics is a biopharmaceutical company that discovers and develops allosteric modulators for human health.

  • 11 - 50

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$4.20M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 of 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus on addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease, and mGlu3 PAM for neurodegenerative disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$4.20M €58M
Addex Therapeutics has raised a total of $4.20M €58M in funding over 2 rounds. Their latest funding was raised on Jul 22, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 22, 2022 Post-IPO Equity $4.20M 1 Armistice Master Fund LTV Detail
Sep 19, 2006 Series C €25M 2 Detail
May 17, 2004 Series B €33M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Addex Therapeutics is funded by 3 investors. Armistice Master Fund LTV and Renaissance are the most recent investors.
Investor Name Lead Investor Funding Round
Armistice Master Fund LTV Yes Post-IPO Equity
Renaissance Series C
Varuma Series C